BOUND BROOK, N.J., Sept. 27, 2023 /PRNewswire/ — SR Bancorp, Inc. (“SR Bancorp”), the holding company for Somerset Regal Bank (the “Bank”), announced today that James Castelletti has been appointed Senior Vice President and Senior Commercial Lending Officer. In his new role, Mr. Castelletti will work with the Bank’s executive leadership team and Board of Directors to continue to diversify and grow the lending portfolio. Mr. Castelletti has extensive experience as a commercial real estate lender, most recently as Vice President – Commercial Real Estate Lender at Northfield Bank, and at Spencer Savings Bank and Wells Fargo Bank.
William P. Taylor, Chairman and Chief Executive Officer of Somerset Regal Bank said: “We are pleased to welcome James to the Somerset Regal Bank team. His deep experience in the lending space and expert knowledge of the local market will prove invaluable to Somerset Regal Bank.”
About Somerset Regal Bank
Somerset Regal Bank, formed in 1887, is a New Jersey commercial bank headquartered in Bound Brook, New Jersey that operates 17 branches in Essex, Hunterdon, Middlesex, Morris, Somerset and Union Counties, New Jersey. Additional information about Somerset Regal is available on its website, www.somersetsavings.com.
Forward-Looking Statements
This press release contains certain forward-looking statements about the reorganization and subscription offering. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” Forward-looking statements, by their nature, are subject to risks and uncertainties.
SOURCE SR Bancorp, Inc.
- Industry veteran with deep commercial experience in dermatology and immunology
- Ayisha Jeter appointed Senior Vice President, Marketing and Market Access
WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie.
“We are truly delighted that Todd is joining Arcutis to take over the leadership of our commercial organization,” said Frank Watanabe, President and CEO of Arcutis. “Over many years, he has developed a deep understanding of what is needed to be commercially successful in dermatology, and his proven track record of successfully commercializing both topical and systemic therapies will be critical in light of our ongoing launch of ZORYVE cream in plaque psoriasis. In addition, we are excited about the impact he will have for topical roflumilast and the expected FDA approvals in other serious skin conditions including seborrheic dermatitis and atopic dermatitis.”
“I am excited to join the Arcutis team and contribute to their efforts in developing and bringing meaningful innovations in immuno-dermatology to market while ensuring responsible pricing and broad accessibility to the individuals who need them,” said Mr. Edwards. “I look forward to working with the Commercial team to accelerate the momentum behind the launch of ZORYVE in plaque psoriasis, and preparing for potential future indications, while advancing Arcutis’ unique company culture focused on challenging the existing standard of care to address unmet needs in the treatment of immune-mediated skin diseases.”
Mr. Edwards joins Arcutis from Incyte, where he was group vice president and business unit head for their immunology business, and led the successful launch and commercialization of their topical JAK inhibitor for atopic dermatitis. Previously, Mr. Edwards was head of US immunology and later head of global immunology operations and strategy for UCB, where he was instrumental in leading commercialization of their dermatology, rheumatology, and gastroenterology portfolios. Prior to that, he held senior roles at AbbVie and TAP Pharmaceuticals. Over the past 25 years, Mr. Edwards has held a wide range of commercial positions of increasing responsibility, spanning sales and sales management, access and reimbursement, marketing, and general management. He is also a decorated veteran of the US Army.
The Company also announced that Ayisha Jeter, Vice President of Market Access, and interim CCO prior to this announcement, has been promoted to Senior Vice President, Marketing and Market Access, and will assume leadership of all marketing and market access at the Company, reporting directly to Mr. Edwards. In her new role, Ms. Jeter will be a member of the Company’s executive leadership team.
“I want to thank Ayisha for the fabulous job she has done as our interim CCO over the last several months as we conducted our search for a permanent CCO,” said Mr. Watanabe. “She brought great leadership and professionalism to the position, and helped us to smoothly navigate the transition of commercial management. This promotion is recognition of her outstanding commercial acumen and leadership.”
About ZORYVE®
ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
IMPORTANT SAFETY INFORMATION
The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
The most common adverse reactions (≥1%) include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
Please see full Prescribing Information.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential for ZORYVE to simplify disease management for care of plaque psoriasis as well as the commercial launch of ZORYVE in plaque psoriasis, and the potential FDA regulatory approvals for topical roflumilast in seborrheic dermatitis, atopic dermatitis and scalp and body psoriasis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 28, 2023, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
emcintyre@arcutis.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aaa7ad47-df63-4ba8-9afb-4d60596062e7
BREA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces its achievement of a key milestone with full approval from the Environmental Protection Agency (“EPA”) with certification for Class 3 EV Commercial Vehicles received on Sept. 22, 2023. Class 3 vehicle production began in August 2023 with the first vehicles rolling off the assembly line on Aug. 21, 2023.
In addition, the Mullen Class 3 EV Cab Chassis Truck has completed all required testing requirements for Federal Motor Vehicle Safety Standards (“FMVSS”) and compliance. With EPA certification in-hand and FMVSS compliance, Mullen can now begin shipments of Class 3 EVs for customer deliveries.
Mullen previously announced on May 2, 2023, a Class 3 vehicle order with Randy Marion Automotive (“RMA”) for 1,000 all-electric cab chassis trucks valued at $63 million. In addition, it was announced on May 11, 2023, that MGT Lease Company (“MGT”), a national fleet leasing provider, will purchase 250 Class 3 EV cab chassis trucks under a contract valued at $15.7 million. On Aug. 28, 2023, Mullen also received an order for Class 3 EV trucks from NRTC Automation Group.
“I am extremely proud of this important milestone and, now with EPA certification and FMVSS in-hand, we are planning to begin Class 3 deliveries this week. Mullen is fully committed to our vision and plan and is focusing in now on deliveries to our customers,” said David Michery, CEO and chairman of Mullen Automotive.
The Mullen THREE is an efficient Class 3 low cab forward EV truck featuring a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,800 pounds of payload. In addition, the design of the LCF chassis allows more cargo volume within a given overall length.
Mullen THREE Vehicle Highlights:
- 130-mile estimated range
- 11,000 lbs. GVWR
- 5,802 lbs. max payload
- 14 ft. max box length
- 38 ft. turning diameter
View full vehicle specifications for the Mullen THREE here.
For further details on EPA certification, including 8-K filling, please visit MullenUSA.com.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.
To learn more about the Company, visit www.MullenUSA.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to the timing of delivery and order completion of the Class 3 vehicles and whether the Class 3 will be a success. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.
Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced the appointment of Gerhard Hagn, PharmD, to the newly created role of SVP, Head of Commercial and Business Development. In this role, Mr. Hagn will oversee commercial and business development strategy and planning.
Gerhard has over two decades of experience as a biopharma executive with commercial expertise in drug development, launches, access and business development. He joins from Gilead Sciences, where he was building the Inflammation business unit and leading the liver franchise as Head of Global Commercial Strategy – Inflammation, Liver & Portfolio. Before Gilead, Gerhard was the Head of Pfizer’s Inflammation & Immunology business unit, responsible for reimbursement, pricing and real-world evidence generation in Rheumatology, Dermatology and Gastroenterology. Gerhard received his degree as “Apotheker” (PharmD) from the Ludwig-Maximilians-Universität in Munich, Germany.
“We are delighted to welcome Gerhard to Tourmaline. He brings decades of experience from Gilead and Pfizer in the inflammation and immunology space across a broad range of indications and is a great addition to our growing team,” said Sandeep Kulkarni, MD, Chief Executive Officer of Tourmaline. “He is joining at a very important time for Tourmaline as our clinical pipeline enters late-stage clinical development. His tremendous insights and capabilities will be invaluable as we plan our commercial footprint and expand our pipeline of potentially transformative medicines to treat immune diseases.”
“With great enthusiasm, I’m joining the Tourmaline team during an exciting time as the company continues to advance its product opportunities across a number of diseases with high unmet medical needs,” said Gerhard. “As we prepare to initiate the Phase 2b clinical trial for our lead program in Thyroid Eye Disease (TED), we stand at the threshold of potentially making substantial contributions to the field of life-altering immune diseases, including TED and cardiovascular disease. Tourmaline’s pioneering efforts in IL-6 blockers, an area with significant untapped potential, open up compelling avenues for commercial and business development. I am excited about bringing my commercial and business development expertise to the team at Tourmaline.”
About Tourmaline Bio, Inc.
Tourmaline Bio is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Tourmaline’s lead program, TOUR006, is an anti-IL-6 antibody that exhibits differentiated properties including high binding affinity to IL-6 and a naturally long half-life. To date, TOUR006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline plans to develop TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. In June 2023, Tourmaline announced it had entered into a definitive agreement with Talaris Therapeutics under which Tourmaline is expected to combine with Talaris. The combined company will operate under Tourmaline’s name and be led by Tourmaline’s current management team, focused on advancing the development of TOUR006.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the development and commercial potential and potential benefits of any product candidates or platform technologies of Tourmaline, including the development and commercial potential of Tourmaline’s lead program, TOUR006, and its potential benefits for life-altering immune diseases, such as Thyroid Eye Disease and cardiovascular disease; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Tourmaline’s control. Tourmaline’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) the uncertainties associated with Tourmaline’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (ii) risks related to the inability of Tourmaline to obtain sufficient additional capital to continue to advance its product candidates and preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; and (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market, among others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the Securities and Exchange Commission (SEC), including the factors described in the section titled “Risk Factors” in Talaris Therapeutic, Inc.’s Registration Statement on S-4 filed with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Tourmaline expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Contacts:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
NewliticQuest offers accelerated insights to inform strategy, optimization and planning
NEW YORK, Sept. 19, 2023 /PRNewswire/ — Newmark Group, Inc. (Nasdaq: NMRK) (“Newmark” or “the Company”), a leading commercial real estate adviser and service provider to large institutional investors, global corporations, and other owners and occupiers, announces the launch of NewliticQuest. Bringing together Newmark’s expertise in real estate, technology and consulting onto a single platform, NewliticQuest offers accelerated insights to develop strategic and tactical recommendations, inform business case development and achieve optimal results for property portfolios. Together with Newlitic, Newmark’s proprietary data visualization platform, NewliticQuest is another addition to Newmark’s growing suite of technology solutions serving corporate real estate leaders.
Leveraging NewliticQuest, organizations are better equipped to plan for and respond to business change, disruptive events, mergers and acquisitions and real estate opportunities through strategic insights, including location and market rate optimization, ideal vacancy rates, talent retention, commute times and more.
“Newmark is committed to investing in leading-edge technology that drives real decision-making dynamics to define the future of the workplace,” said Rick Bertasi, Chief Executive Officer of Newmark Global Corporate Services. “Given the changing nature of corporate real estate, technology advancements will further amplify the value and potential of an organization’s real estate strategy as companies pivot towards more data-centric cultures.
NewliticQuest offers several self-serve capabilities and insights into business and real estate performance with dynamic and simple dashboards, which can be accessed directly by clients. The software’s automated data validation capabilities help users quickly pinpoint data issues to ensure that information is accurate before being executed. Coupled with Newmark’s best-in-class consulting expertise, the tool can enable in-depth portfolio assessment, delivering tailored and tangible solutions for clients assessing their portfolio.
About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the year ending December 31, 2022, Newmark generated revenues of approximately $2.7 billion. As of June 30, 2023, Newmark’s company-owned offices, together with its business partners, operate from approximately 170 offices with over 7,400 professionals around the world. To learn more, visit nmrk.com or follow @newmark.
Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
SOURCE Newmark Group, Inc.
BREA, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) — via IBN – Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces the Company has received approval from the IRS, receiving its “qualified manufacturer” designation enabling qualification for commercial EV federal tax credits of up to $7,500 per qualified vehicle with gross vehicle weight ratings (GVWRs) of under 14,000 pounds.
The company is pleased to announce that both the Mullen ONE, a Class 1 EV Cargo Van, and the Mullen THREE, a Class 3 EV Cab Chassis Truck, are now approved for EV federal tax credits of up to $7,500 per qualified vehicle. Additionally, according to the relevant IRS regulation, vehicles with gross vehicle weight ratings (GVWR) of over 14,000 pounds can qualify for $40,000 federal EV tax credits.
Mullen received this designation on Sept. 14, 2023, as a “Qualified Manufacturer” as defined in § 30D(d)(3) of the Internal Revenue Code.
Mullen Automotive will be listed as a Qualified Manufacturer on irs.gov (note, the Company was informed that it may take up to 2 weeks for the Company’s name to post on the site). The full Qualified Manufacturer index can be found on IRS.gov.
“Total cost of ownership is critically important to commercial customers. Tax credits such as these, along with lower fuel and maintenance costs, show a clear advantage for Mullen’s commercial offerings compared to traditional internal combustion vehicles,” said John Schwegman, chief commercial officer of Mullen Automotive.
“This is part of fulfilling our commitment to customers. This presents a great opportunity to purchase a commercial vehicle while optimizing all available federal incentives,” said David Michery, CEO and chairman of Mullen Automotive.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen I-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs, and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.
To learn more about the Company, visit www.MullenUSA.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to when the Company’s name will post on the relevant IRS site and whether the tax credits will improve vehicle sales. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.
Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
BREA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces the launch of Commercial Pulse, an advanced telematics solution for customers providing a complete solution for vehicle diagnostics and fleet optimization.
Mullen’s Commercial Pulse is an advanced telematics AI system providing drivers and fleet companies a connected fleet of vehicles with maintenance alerts, real-time vehicle location, driver safety, battery state of charge, metrics and more. The end-user dashboard features asset and trip management, electric vehicle and driver performance, geofencing and reporting.
Commercial Pulse is available via two mobile applications – Mullen Commercial Pulse Fleet and Mullen Commercial Pulse Driver – on both iOS and Android platforms. Mullen Commercial Pulse Fleet provides insights and access, including a variety of management functions like vehicle health, maintenance, battery and safety/security alerts. Mullen Commercial Pulse Driver improves driver practice and time management with features like routing assistance, real-time vehicle location, charging station locator and roadside assistance.
“We are excited to introduce Commercial Pulse, a fleet telematics software maximizing uptime and providing the tools and data needed to manage vehicle operations,” said John Schwegman, Mullen’s Chief Commercial Officer. “As we have seen in our early customer pilots and engineering fleet, and by continuously monitoring vehicle performance, our system can detect potential maintenance issues before breakdowns empowering businesses to streamline operations and enhance efficiencies.”
“In an era where data is all around us, Commercial Pulse provides fleet managers with an easy-to-understand dashboard with information needed to optimize fleets and driver operations,” said David Michery, Mullen’s CEO. “It’s an exciting time when we can showcase the fleet efficiencies, emissions savings, and energy reduction on our commercial portfolio.”
Commercial Pulse is currently available for the Mullen ONE, all-electric Class 1 Cargo Van, and Mullen THREE, all-electric Class 3 Low Cab Forward.
Access to Commercial Pulse is subject to vehicle purchase and eligible subscription.
Learn more about Commercial Pulse today.
About Mullen
Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen I-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.
To learn more about the Company, visit www.MullenUSA.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to whether the Commercial Plus product will perform as expected. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.
Contact:
Mullen Automotive Inc.
+1 (714) 613-1900
www.MullenUSA.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
HOUSTON, Sept. 18, 2023 /PRNewswire/ — KBR (NYSE: KBR) announced today it has been awarded a license and engineering design contract by Hanwha Impact Corporation for the world’s first commercial ammonia cracking unit using KBR’s leading H2ACTSM technology in Daesan, Republic of Korea.
In this largest capacity ammonia cracking plant announced to date, clean hydrogen will serve a planned power plant in Daesan, paving the way for large-scale sustainable hydrogen utilization. Ammonia cracking, the process to convert transported ammonia back to hydrogen, is a key enabler to achieving the world’s decarbonization target.
Under the terms of the contract, KBR will provide technology licensing and proprietary engineering design for the unit, which will be designed to deliver over 200 metric tons per day of clean hydrogen as fuel.
“We are honored to be selected by Hanwha for this flagship project, which will accelerate the realization of their decarbonization targets and play a vital role in Korea’s national sustainability objectives,” said Doug Kelly, President, Technology, KBR. “KBR’s breakthrough ammonia cracking technology, H2ACT, delivers a reliable and holistic solution for large-scale, efficient, and sustainable hydrogen production.”
KBR is a world leader in ammonia technology. Since 1943, KBR has licensed and designed more than 250 ammonia plants across the globe.
About KBR
We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 33,000 people performing diverse, complex and mission-critical roles in 33 countries.
KBR is proud to work with its customers across the globe to provide technology, value-added services, and long-term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.
Visit www.kbr.com
Forward Looking Statements
The statements in this press release that are not historical statements, including statements regarding the performance of the company’s contract with Hanwha Impact Corporation, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
SOURCE KBR, Inc.
Public Storage Acquired Simply Self Storage from Blackstone Real Estate Income Trust, Inc.
NEW YORK, Sept. 15, 2023 /PRNewswire/ — Newmark Group, Inc. (Nasdaq: NMRK) (“Newmark” or “the Company”), a leading commercial real estate adviser and service provider to large institutional investors, global corporations, and other owners and occupiers, announces it served as the Co-Lead Advisor to Blackstone Real Estate Income Trust, Inc. (“BREIT”) on its sale of Simply Self Storage (“Simply”) to Public Storage for $2.2 billion. Newmark’s Capital Markets National Self Storage practice leader Vice Chairman Aaron A. Swerdlin and team advised BREIT on the transaction.
The portfolio comprises 127 wholly-owned properties and 9 million net rentable square feet that are geographically diversified across 18 states and located in markets with population growth that has been approximately double the national average since 2018. Approximately 65% of the properties are located in high-growth Sunbelt markets.
“Self-storage is an asset class that continues to perform, even amidst the current challenging capital markets environment,” Swerdlin said. “In fact, the asset class, bolstered by its strong historical performance across business cycles, continues to garner a disproportionate share of overall commercial real estate transaction activity. We’re thrilled to have been able to advise our client on this sale.”
Public Storage funded the acquisition by utilizing its growth-oriented balance sheet to issue $2.2 billion of senior unsecured notes and quickly closed the transaction in a well-coordinated effort with the Simply and Blackstone teams. Public Storage expects the transaction will be accretive to FFO per share, with accretion accelerating through stabilization. A presentation with further detail is available on the Investor Relations section of PublicStorage.com.
About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the year ending December 31, 2022, Newmark generated revenues of approximately $2.7 billion. As of June 30, 2023, Newmark’s company-owned offices, together with its business partners, operate from approximately 170 offices with over 7,400 professionals around the world. To learn more, visit nmrk.com or follow @newmark.
Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
SOURCE Newmark Group, Inc.
HOUSTON, Sept. 14, 2023 /PRNewswire/ — KBR (NYSE: KBR) announced today that its commercial cloud and mission service platform, KBR Vaault®, has been prioritized for the Federal Risk and Authorization Management Program (FedRAMP®) Joint Authorization Board (JAB) authorization process.
KBR’s integrated technology solution is one of only six products currently prioritized for JAB authorization as a part of FedRAMP, a joint U.S. government effort to provide thoroughly reviewed, cost-effective and risk-based cloud services.
KBR built the platform from the ground up to support U.S. federal government agencies and announced its listing on the FedRAMP marketplace last year. KBR Vaault® supports a variety of domain-specific solutions, including public safety, health and human performance, mission operations, asset management and the Internet of Things (IoT). The secure, cloud-based platform provides customers with an integrated system that allows for rapid deployment and custom configuration while remaining compliant with federal cybersecurity guidelines at the highest level.
“Cloud security is key to a growing number of customer missions, and going through JAB’s rigorous authorization process supports our readiness to meet our customers’ needs,” said Byron Bright, President of KBR Government Solutions U.S. “We value this prioritization by FedRAMP because it will help us deliver this critical capability to even more customers.”
The KBR Vaault® team has key experience working with U.S. Army law enforcement and the U.S. Air Force public safety community. For additional details about the KBR Vaault® solution, visit kbr.com/kbrvaault or contact [email protected].
About KBR
We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 33,000 people performing diverse, complex and mission-critical roles in 33 countries.
KBR is proud to work with its customers across the globe to provide technology, value-added services, and long-term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.
Visit www.kbr.com
Forward Looking Statements
The statements in this press release that are not historical statements, including statements regarding future demand for KBR products and services, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
SOURCE KBR, Inc.
